Announcements - OBI Pharma 台灣浩鼎

2021.Apr.07

OBI’s application to initiate the Phase III clinical study of the active cancer immunotherapy OBI-822 (Adagloxad Simolenin) has been denied by the Ministry of Health, Argentina

2021.Mar.17

OBI filed the application to EMA for Phase III human clinical study of the active cancer immunotherapy OBI-822, Adagloxad Simolenin, in Spain, German, and Poland

2021.Mar.12

The Board of Directors resolved to hold 2021 Annual General Meeting

2021.Mar.12

Announcement of not Distributing Dividends in 2020

2021.Mar.12

Announcement of 2020 Consolidated Financial Report

2021.Mar.12

OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations of Mexico

2021.Feb.23

OBI licensed “OBI-858 Novel Botulinum Toxin Preparation” Intellectual Property Right of Global Aesthetic Medicine to OBIGEN Pharma, Inc.

2021.Feb.17

OBI filed the application of Phase III human clinical study for the active cancer immunotherapy OBI-822, Adagloxad Simolenin, to the drug administrations in Argentina, Brazil, and South Africa

2021.Jan.26

Mr. Michael Chang and five other executives received an acquittal for insider trading case at second instance by Taiwan High Court

2021.Jan.06

OBI Pharma Inc. to attend the 39th Annual J.P. Morgan Healthcare Conference

News

Latest News

Events

Latest events